You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 83 No. 1, January 1961 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Chloroquine for Chronic Discoid Lupus Erythematosus

Intralesional Injections

ALFRED PELZIG, M.D.; VICTOR H. WITTEN, M.D.; MARION B. SULZBERGER, M.D.

Arch Dermatol. 1961;83(1):146-148.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It is not unusual to see one, or perhaps a few residual lesions of various dermatoses which have failed to respond to an otherwise successful regimen of therapy.1 Examples are the persistent penile plaque of distinctive exudative discoid and lichenoid chronic dermatosis (Sulzberger-Garbe), the single or few persistent lesions of psoriasis, lichen planus, pemphigus, discoid lupus erythematosus, and others.

This report concerns primarily the residual lesions of chronic discoid lupus erythematosus.

It is well known that isolated lesions of chronic discoid lupus erythematosus may be treated by various local applications, e.g., various acids, solid carbon dioxide, and the intralesional injection of gold compounds.2,3 Recently, we became interested in the report of Ottolenghi-Lodigiani,4 on the combined intralesional and oral administration of quinacrine (Atabrine) and the report of Thies,5 on the favorable effects of chloroquine used intralesionally as well as systemically.

For our purposes, chloroquine dichloride, 50 mg. . . . [Full Text PDF of this Article]


Author Affiliations

NEW YORK

From the Department of Dermatology and Syphilology, New York University Medical Center (Dr. Marion B. Sulzberger, Chairman), Skin and Cancer Unit, University Hospital.


Footnotes

Submitted for publication Aug. 3, 1960.

This paper was written with the assistance of Sidney Clyman, M.D., and Jorge E. Close, M.D. (Policlinica: 7A. AV. 14-12, Guatemala, C.A.).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1961 American Medical Association. All Rights Reserved.